Codeine for Cough in Adults
Codeine should be reserved exclusively for short-term symptomatic relief of chronic bronchitis-related cough in adults and is NOT recommended for acute upper respiratory infections or common cold-related cough. 1
When Codeine IS Appropriate
Indication
- Chronic bronchitis only - Codeine is recommended as a central cough suppressant specifically for chronic bronchitis when short-term symptomatic relief is needed 1
- Evidence level: Fair quality, intermediate benefit, Grade B recommendation 1
Dosing (from FDA labeling)
- Adults and children ≥12 years: 10 mg (2 teaspoons/10 mL) every 4 hours 2
- Maximum: 6 doses in 24 hours (60 mg/day total) 2
- Real-world data shows median daily doses of 30 mg/day with treatment durations of 27.5 days median 3
Duration
- Short-term use only - Guidelines emphasize brief symptomatic relief 1
- Real-world practice shows 14% of patients receive codeine >8 weeks, though this exceeds guideline recommendations 3
- Monitor closely; discontinue once cough improves
When Codeine is NOT Appropriate
Contraindicated/Not Recommended For:
- Upper respiratory infections (URI)/common cold - Grade D recommendation (good evidence, no benefit) 1
- A controlled trial demonstrated codeine 30 mg four times daily was no more effective than placebo for acute URI cough 4
- Acute cough <3 weeks duration - Should follow acute cough algorithm focusing on identifying underlying cause 5
- Children <6 years - Requires physician consultation per FDA labeling 2
Clinical Algorithm
Determine cough duration first - This is the critical initial step 5
- Acute (<3 weeks): Treat underlying cause
- Subacute (3-8 weeks): Evaluate for post-infectious causes
- Chronic (>8 weeks): Systematic evaluation needed
For chronic cough, identify the specific etiology 5:
- Screen for red flags (hemoptysis, weight loss, smoker >45 years with new cough, dyspnea at rest)
- Most common causes: Upper airway cough syndrome, asthma, GERD, nonasthmatic eosinophilic bronchitis
- Environmental/occupational exposures
- ACE inhibitor or sitagliptin use
Consider codeine ONLY if:
- Diagnosis is chronic bronchitis
- Need short-term symptomatic relief while treating underlying cause
- Patient is ≥12 years old
- No contraindications to opioids
Use validated cough severity tools to assess response 5:
- Visual Analog Scale (VAS)
- Leicester Cough Questionnaire (LCQ)
- Cough Symptom Score (CSS)
Follow-up within 4-6 weeks of initial evaluation 5
Important Caveats and Pitfalls
Common Pitfalls:
- Overuse in viral URIs - Despite widespread use, codeine has no proven efficacy for common cold cough 1, 4
- Prolonged use - Real-world data shows 14% receive >8 weeks of treatment, which exceeds evidence-based recommendations 3
- Using as first-line without diagnosis - Codeine should not replace proper diagnostic evaluation of chronic cough 5
Side Effects to Monitor:
- Drowsiness, constipation, and headaches are most common 6
- Reported in 7.8% of patients in real-world practice 3
- Most adverse events are mild and non-serious 7, 6
- Opioid effects relate to CYP2D6 metabolism to morphine 8
Alternative Considerations:
- Ipratropium bromide is the only recommended inhaled anticholinergic for URI or bronchitis cough (Grade A) 1
- Peripheral cough suppressants (levodropropizine, moguisteine) are Grade A for acute/chronic bronchitis 1
- Recent comparative data shows codeine more effective than levodropropizine for chronic cough (VAS improvement 35.11 vs 19.77 points, p=0.002) but with more side effects 6
Key Contraindication:
- Do NOT use mucolytic agents for cough suppression in chronic bronchitis (Grade D) 1
Nuances in the Evidence
The 2018 CHEST guidelines 5 updated the chronic cough algorithm but did not change the 2006 recommendations 1 regarding codeine use. The evidence base remains limited to chronic bronchitis with fair-quality evidence. The lack of efficacy in URI is supported by controlled trials 4, making the distinction between chronic bronchitis and acute viral illness critical for appropriate prescribing.